Presenter: Dr. Andrew G. Hadd, Ph.D., Senior Scientist, Diagnostic Research & Technology Development, Asuragen, Inc. Abstract: Learn how Asuragen is applying the RainDance DeepSeq Solution to commercialize cancer prevention and research tools for their customers. Dr. Andrew Hadd,
New RainDrop™ System surpasses all existing digital PCR technologies and establishes new performance standards in cancer research LEXINGTON, Mass. AND CHICAGO, Ill., April 2, 2012 – RainDance Technologies, Inc., the Digital Biology™ company, today introduced its new RainDrop™ Digital
Cancer “HotSpot” Panel enables customers to sequence, in a single assay, more than 13,000 mutations associated with cancer progression and resistance to therapy LEXINGTON, Mass. AND CHICAGO, Ill., April 2, 2012 – RainDance Technologies, Inc., the Digital Biology™ company, today announ
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.